Curis Files Prospectus Related To The Resale Of Up To 33,333,360 Common Shares
HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $6
Curis (CRIS) Q3 2026 Earnings Call Transcript
Curis: Q3 Earnings Snapshot
Curis Provides Third Quarter 2026 Business Update
Curis, Inc. (CRIS) Q3 2026 Earnings Call Transcript
Curis Q3 EPS $(1.94) Beats $(2.01) Estimate
Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026
Curis Shares Surge 70.7% as Reverse Stock Split Vote and Upcoming Clinical Data Attract Investors
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
Curis Commences ~$8.5M Offering Of 16.666M Common Shares, Warrants At $0.51 Per Share
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $43 Price Target
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework
Curis Doses First Five Patients in TakeAim CLL Study
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.